Skip to main content
< Back
About
About the conference
App
Organisers & Partners
Latest updates
Press room
Registration
Venue 22
About the venue
Rooms
Call for abstracts
Programme 22
Tracks 22
Speakers 22
Side events 22
Subscribe
days
hours
minutes
seconds
Medicines
Sessions
Wednesday, 23 November
09:00
Ensuring adequate pain relief whilst reducing addiction risk: lessons learnt and the way forward
09:00
to
10:30
Main stage
Sarah Welch
10:50
Improving knowledge, taking action
10:50
to
12:20
Networking zone 1 (N1)
Eilish Gilvarry
Prescription opioids and overdose deaths
10:50
to
12:20
Knowledge market 1 (K1)
Thomas Clausen
Substance-induced psychosis: register-linkage research in Nordic countries
10:50
to
12:20
Knowledge market 2 (K2)
Solja Niemelä
13:20
e-/m-health interventions for substance use disorders
13:20
to
14:50
Central square 3 (C3)
Peter J. Adams
Precision Medicine and Novel Approaches to the Treatment Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
15:00
Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances
15:00
to
16:30
Central square 2 (C2)
Ana Gallegos,
Roumen Sedefov
Estimating harm
15:00
to
16:30
Central square 3 (C3)
Xavier Majó Roca
Short communications on alcohol: Covid, Ketamine, Cognition, Consumption
15:00
to
16:30
Networking zone 3 (N3)
Cristina Ribeiro
16:50
Driving under the influence of cannabis (DUIC)
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Improving the health of people who use drugs
16:50
to
18:20
Networking zone 4 (N4)
Magdalena Harris
Thursday, 24 November
09:00
Contemporary Issues
09:00
to
10:30
Central square 2 (C2)
Anne Line Bretteville-Jensen
10:50
Interventions in Community
10:50
to
12:20
Networking zone 1 (N1)
Elena Gervilla
Practitioners informing practice
10:50
to
12:20
Knowledge market 3 (K3)
Gerhard Buhringer
13:20
Uppers, downers and psychedelics
13:20
to
14:50
Networking zone 3 (N3)
Harry Sumnall
16:50
New frontiers to regulating cannabis for public health and social justice
16:50
to
18:20
Insights zone 2 (I2)
Simon Lenton
Trajectories of cannabis use during periods of policy change
16:50
to
18:20
Central square 2 (C2)
Rosalie Pacula
Friday, 25 November
13:20
Understanding drug use, risk and harm
13:20
to
14:50
Networking zone 2 (N2)
Henrique Lopes
Presentations
e-poster
Methamphetamine Addiction in the South- East Nigeria And The Community Approach : The Way Forward
Networking zone 1 (N1)
Gladys Chibuzor
e-poster
Risk reduction and health promotion for transgender substance users: a systematic review of activist literature
Networking zone 1 (N1)
Anna Baleige
Short communication
Cognitive Functions in Early- Detoxified Alcohol-Dependent Inpatients and Their Association with Severity of Alcohol Dependence
Networking zone 3 (N3)
Prabhoo Dayal
Short communication
Efficacy of Cognitive Retraining Module for improving Cognitive Deficits of abstinent patients with Alcohol Dependence Syndrome and Opioid Dependence Syndrome in a Tertiary Care De-addiction Centre of Northern India
Networking zone 3 (N3)
Gauri Shanker Kaloiya
Oral presentation
Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project
Networking zone 4 (N4)
Cristiana Merendeiro
Short communication
Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review
Networking zone 4 (N4)
João Pedro Ramos
e-poster
Prolonged DAM-take-home in times of Covid-19:harm reduction or increase?
Networking zone 1 (N1)
Franciska Brezan
Oral presentation
Medical cannabis in professional education: Assessment of students from Malta, Israel and Russia
Knowledge market 3 (K3)
Yuval Zolotov
e-poster
Changes in sexualised and non-sexualised drug use among LGBT+ people during the COVID-19 pandemic: A systematic review
Networking zone 2 (N2)
Dean Connolly
e-poster
Abuse of prescription psychoactive medicines
Networking zone 2 (N2)
Darja Lavtar
e-poster
Suicide and self-harm among people prescribed opioid agonist treatment in New South Wales: a retrospective data linkage study
Networking zone 2 (N2)
Samantha Colledge-Frisby
Wednesday, 23 November
09:00
Keynote presentation
EFIC recommendations: When to use opioids for chronic pain and when not to
09:00
to
10:30
Main stage
Winfried Häuser
Keynote presentation
Pain and the opioid overdose crisis in the U.S.: experiences, lessons learned, and the path forward
09:00
to
10:30
Main stage
Christopher M. Jones
Keynote presentation
Changing perspectives on the use of medicines for pain
09:00
to
10:30
Main stage
Cathy Stannard
10:50
Oral presentation
3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study
10:50
to
12:20
Knowledge market 2 (K2)
Heidi Taipale
Oral presentation
4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections
10:50
to
12:20
Knowledge market 2 (K2)
Jørgen G. Bramness
Oral presentation
5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Jeyaniroshan Jeyapalan
Oral presentation
1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
10:50
to
12:20
Knowledge market 2 (K2)
Eline Borger Rognli
Oral presentation
2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study
10:50
to
12:20
Knowledge market 2 (K2)
Pihla Sassi
Oral presentation
1. Characteristics of suicides among overdose deaths in Norway in 2016-2020
10:50
to
12:20
Knowledge market 1 (K1)
Hilde Marie Erøy Edvardsen
Oral presentation
2. Individuals dying of overdoses related to pharmaceutical opioids differ from individuals dying of overdoses related to other substances
10:50
to
12:20
Knowledge market 1 (K1)
Svetlana Skurtveit
Oral presentation
3. Changes in primary cause of overdose deaths following liberalisations in opioid prescription practices and differences in overdose death correlates.
10:50
to
12:20
Knowledge market 1 (K1)
Linn Gjersing
Oral presentation
4. Fatal overdoses in a cohort of chronic pain patients
10:50
to
12:20
Knowledge market 1 (K1)
Aleksi Hamina
e-poster
Barriers and Facilitators to Accessing Inpatient and Community Substance Use Treatment and Harm Reduction Services for People Who Use Drugs in Muslim Communities: A Systematic Narrative Review of Studies on Service Users and Providers Experiences
10:50
to
12:20
Networking zone 1 (N1)
Qutba Al Ghafri
e-poster
Prevalence of HCV infection in vulnerable populations: DETECT-C program a real contribution to hepatitis C elimination in these groups in Spain
10:50
to
12:20
Networking zone 1 (N1)
Francisco Pascual
e-poster
ABC Training for Alcohol Use During an Abstinence Challenge (IkPas/NoThanks!): a pilot study
10:50
to
12:20
Networking zone 1 (N1)
Ting Pan
e-poster
Drug death related bereavement and recovery (The END-project)
10:50
to
12:20
Networking zone 1 (N1)
Birthe Møgster
e-poster
Effects of prolonged diacetylmorphine take-home prescription in Heroin assisted treatment in Switzerland
10:50
to
12:20
Networking zone 1 (N1)
Jonas Montagna
e-poster
Predicting the long-term effect of e-cigarette use on population health: A systematic review of modelling studies
10:50
to
12:20
Networking zone 1 (N1)
Giang Vu
13:20
Discussion
New Directions in Behavioral and Pharmacological Treatments and Precision Medicine Approaches for Improving Rates of Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Karl Mann
Oral presentation
1. ABC-Training: A New Proposition-Based Variety of Cognitive Bias Modification. Theoretical Background and Initial Results.
13:20
to
14:50
Central square 1 (C1)
Reinout W. Wiers
Oral presentation
2. Phenotyping Individuals with Alcohol Use Disorder: Implications for Precision Medicine and Predicting Non-Abstinent Recovery from Alcohol Use Disorder
13:20
to
14:50
Central square 1 (C1)
Katie Witkiewitz
Oral presentation
3. Examining a Brief Measure and Observed Cutoff Scores to Identify Reward and Relief Drinking Profiles: Psychometric Properties and Pharmacotherapy Response
13:20
to
14:50
Central square 1 (C1)
Victoria R. Votaw
Oral presentation
Discontinuing chronic benzodiazepine use for insomnia with blended care: results of a pragmatic cluster-RCT
13:20
to
14:50
Central square 3 (C3)
Kristien Coteur
Oral presentation
A cluster randomised controlled trial of an eHealth intervention to prevent multiple lifestyle risk behaviours among Australian adolescents: Results from the Health4Life Study
13:20
to
14:50
Central square 3 (C3)
Katrina Champion
Oral presentation
Digital technologies to prevent drug overdoses. A UK perspective
13:20
to
14:50
Central square 3 (C3)
Alberto Oteo
Oral presentation
Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine
13:20
to
14:50
Central square 3 (C3)
Krista Siefried
15:00
Short communication
This Is Something That Changed My Life': A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders
15:00
to
16:30
Networking zone 3 (N3)
Merve Mollaahmetoglu
Short communication
Changes in retrospectively recalled alcohol use and hazardous drinking pre, during, and post an alcohol sales prohibition in Botswana during COVID pandemic.
15:00
to
16:30
Networking zone 3 (N3)
J. Maphisa Maphisa
Short communication
Exploring the potential for Managed Alcohol Programmes during the COVID-19 pandemic in Scotland: Findings from a mixed methods study
15:00
to
16:30
Networking zone 3 (N3)
Hannah Carver
Short communication
Consumption of alcohol, tobacco and lifestyles in the population over 50 years old: Perception of quality and satisfaction with life
15:00
to
16:30
Networking zone 3 (N3)
Filipa Coelhoso
Short communication
Managed alcohol program in the low-threshold daily facility in the City of Brno, Czech Republic.
15:00
to
16:30
Networking zone 3 (N3)
Petr Blažek
Short communication
Thirty years of experience in Alcoholism treatment
15:00
to
16:30
Networking zone 3 (N3)
Inês Azevedo Silva
Oral presentation
Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.
15:00
to
16:30
Central square 3 (C3)
Tisdale Calvert
Oral presentation
It is logically not possible to quantify the number of indirect deaths
15:00
to
16:30
Central square 3 (C3)
Alfred Uhl
Oral presentation
Mortality and Morbidity in Patients in Opioid Maintenance Treatment
15:00
to
16:30
Central square 3 (C3)
Roman Gabrhelík
Oral presentation
Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.
15:00
to
16:30
Central square 3 (C3)
Charlotte Buckley
Oral presentation
Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project
15:00
to
16:30
Central square 3 (C3)
Ana Araújo
Oral presentation
5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines
15:00
to
16:30
Central square 2 (C2)
Dilkushi Poovendran
Oral presentation
1. Early warning on emerging drug threats at the international level – opportunities and challenges
15:00
to
16:30
Central square 2 (C2)
Martin Raithelhuber
Oral presentation
2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe
15:00
to
16:30
Central square 2 (C2)
Michael Evans-Brown
Oral presentation
3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety
15:00
to
16:30
Central square 2 (C2)
Luli R. Akinfiresoye,
Terrence L. Boos
Oral presentation
4. NPS Discovery: An Open Access Early Warning System for the United States
15:00
to
16:30
Central square 2 (C2)
Barry K. Logan
16:50
Short communication
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial
16:50
to
18:20
Networking zone 4 (N4)
Arne Skulberg
Short communication
Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network
16:50
to
18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication
Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study
16:50
to
18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication
Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study
16:50
to
18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Short communication
Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.
16:50
to
18:20
Networking zone 4 (N4)
Peter McCarron
Short communication
The role of a medically supervised injecting room in improving access to health and social services.
16:50
to
18:20
Networking zone 4 (N4)
Nico Clark
Oral presentation
4. Policy and legislation
16:50
to
18:20
Insights zone 3 (I3)
Brendan Hughes
Oral presentation
5. Medical use and novel cannabinoids
16:50
to
18:20
Insights zone 3 (I3)
Robyn Robertson
Oral presentation
1. Experimental studies on cannabis and driving impairment
16:50
to
18:20
Insights zone 3 (I3)
Tom Arkell
Oral presentation
2. Epidemiological studies on cannabis and crash risk
16:50
to
18:20
Insights zone 3 (I3)
Eef Theunissen
Oral presentation
3. Toxicology: detection of THC impairment
16:50
to
18:20
Insights zone 3 (I3)
Jan Ramaekers
Short communication
Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway
16:50
to
18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Thursday, 24 November
09:00
Oral presentation
Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field
09:00
to
10:30
Central square 2 (C2)
Tuulia Lerkkanen
Oral presentation
Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission
09:00
to
10:30
Central square 2 (C2)
Zoe Ward
Oral presentation
Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme
09:00
to
10:30
Central square 2 (C2)
Gail Gilchrist
Oral presentation
ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia
09:00
to
10:30
Central square 2 (C2)
Fred Cameron
10:50
e-poster
When substance use meets sexuality: perspectives of gays, bisexuals and men having sex with men (gbMSM) regarding their sexualized drug use
10:50
to
12:20
Networking zone 1 (N1)
Maxime Blanchette
e-poster
Bridges in Prevention: a community-based multi-component intervention model
10:50
to
12:20
Networking zone 1 (N1)
Carla Frazão
e-poster
Non-medical use of ADHD medication among Dutch college students
10:50
to
12:20
Networking zone 1 (N1)
Michelle van der Horst
e-poster
SIPAFS Platform - A contribution to the Digital Transformation of the Plano Operacional deRepostas Integradas
10:50
to
12:20
Networking zone 1 (N1)
Bruno Freitas
e-poster
Police, firefighters, urban cleaners, drivers, gardeners and gravediggers and risk behaviors related to Alcohol, Tobacco, Obesity and Sleep: different professions, different consumption, different interventions?
10:50
to
12:20
Networking zone 1 (N1)
Jorge Barroso-Dias
e-poster
Training of trainers and monitoring implementation of evidence based drug prevention in Pakistan
10:50
to
12:20
Networking zone 1 (N1)
Johan Jongbloet
e-poster
French chemsex project
10:50
to
12:20
Networking zone 1 (N1)
Jonathan Rayneau
e-poster
Process evaluation of the Belgian one-month-abstinence campaign ‘Tournée Minérale’
10:50
to
12:20
Networking zone 1 (N1)
Annelies Thienpondt
Oral presentation
Administration matters! A retrospective cohort study of medication dispensing at pharmacies
10:50
to
12:20
Knowledge market 3 (K3)
Birgitte Thylstrup
Oral presentation
Primary Care Provider expectations of addiction services and patients in Spain.
10:50
to
12:20
Knowledge market 3 (K3)
Pablo Barrio
Oral presentation
Optimising take home naloxone intervention delivery in the community (retail) pharmacy setting.
10:50
to
12:20
Knowledge market 3 (K3)
Jennifer Scott
Oral presentation
Practitioner perspectives on working with older patients in opioid agonist treatment (OAT) in Norway
10:50
to
12:20
Knowledge market 3 (K3)
John Todd-kvam
Oral presentation
Integrating harm reduction in homelessness services. The HR4H Key Principles
10:50
to
12:20
Knowledge market 3 (K3)
Roberto Perez Gayo
13:20
Short communication
Harm Reduction for Chemsex in Lisbon: community-based interventions for a hard-to-reach group, during the COVID-19 pandemic
13:20
to
14:50
Networking zone 3 (N3)
Filipe Couto Gomes
Short communication
Z-Drugs Dependence: An Awakening Truth
13:20
to
14:50
Networking zone 3 (N3)
Afonso Homem De Matos
Short communication
Evaluating Cracks in the Ice – a digital health initiative to support families, health workers and communities affected by crystal methamphetamine (‘ice’)
13:20
to
14:50
Networking zone 3 (N3)
Steph Kershaw
Short communication
Exclusive therapeutic use of cannabis in France: characteristics and use patterns in a large sample of daily users
13:20
to
14:50
Networking zone 3 (N3)
Martin Bastien
Short communication
Psychoactive substance use among Serbian adults – results from online survey
13:20
to
14:50
Networking zone 3 (N3)
Biljana Kilibarda
Short communication
The epigenetic effects of cannabis exposure and their link to behavior and emotional manifestations – a scoping review
13:20
to
14:50
Networking zone 3 (N3)
Ana Sofia Machado
16:50
Oral presentation
Trajectories of Prescribed Medical Cannabis Filled Over Time
16:50
to
18:20
Central square 2 (C2)
Alexandra Kritikos
Oral presentation
Medical cannabis regulation: Taking the best of the North American and European models
16:50
to
18:20
Insights zone 2 (I2)
Davide Fortin
Oral presentation
Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada
16:50
to
18:20
Insights zone 2 (I2)
Christophe Huynh
Oral presentation
Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in
16:50
to
18:20
Insights zone 2 (I2)
François Gagnon
Oral presentation
Regulating Cannabis for Public Health
16:50
to
18:20
Insights zone 2 (I2)
Seema Pessar
Oral presentation
Mitigating the risks of corporate capture in emerging legal cannabis markets
16:50
to
18:20
Insights zone 2 (I2)
Stephen Rolles
Oral presentation
Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.
16:50
to
18:20
Insights zone 2 (I2)
Gaby Mohr
Oral presentation
Differences in cannabis use and opinions on drug policy between generations
16:50
to
18:20
Central square 2 (C2)
Pekka Hakkarainen
Oral presentation
Adolescent cannabis use during a period of rapid policy change: Evidence from the US PATH Study
16:50
to
18:20
Central square 2 (C2)
Mike Vuolo
Oral presentation
The role played by evidence on the effects of cannabis use in cannabis policy 1992-2022
16:50
to
18:20
Central square 2 (C2)
Eva Hoch
Friday, 25 November
13:20
e-poster
Changes in substance use during the COVID-19 pandemic: Longitudinal analysis of risk behavior and mental health of MSM using HIV pre-exposure prophylaxis
13:20
to
14:50
Networking zone 2 (N2)
Babette Lea Winter
e-poster
Non-prescribed buprenorphine and reduction in illicit opioids use among individuals with opioid use disorder: a longitudinal study
13:20
to
14:50
Networking zone 2 (N2)
Raminta Daniulaityte
e-poster
Sexualized substance use, consumption motives and risk factors for relapse of addiction patients. Results of a cross-sectional study in addiction treatment facilities in Germany.
13:20
to
14:50
Networking zone 2 (N2)
Daniel Deimel
e-poster
How hair keeps track: Associations between hair concentrations of psychoactive substances and steroid hormones in a large cohort sample of young adults in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Lydia Johnson-Ferguson
e-poster
Four-year long wastewater-based monitoring of illicit drug consumption pilot project in Switzerland
13:20
to
14:50
Networking zone 2 (N2)
Livia Andrani
e-poster
How are profiles of substance use linked to social function in the following seven years?
13:20
to
14:50
Networking zone 2 (N2)
Sidsel Karsberg
e-poster
A systematic review of self-report and behavioural measures of the Addiction Neuroclinical Assessment constructs of incentive salience and negative emotionality, in adults who use psychoactive drugs.
13:20
to
14:50
Networking zone 2 (N2)
Maria Bravo Aguilera